source
- AusperBio secures $120 million Series C to push hepatitis B antisense therapy into Phase 3AusperBio Therapeutics announced it has closed a $120 million Series C financing round aimed at moving its hepatitis B antisense oligonucleotide candidate toward late‑stage trials and eventual mark…
- Roche pays $190 million for rights to Hanmi's UCN2 analog targeting obesity with muscle-preserving effectsRoche's Genentech unit has agreed to pay $190 million upfront for rights to HM17321, a urocortin‑2 analog developed by South Korea’s Hanmi Pharmaceutical, covering markets outside South Korea. The…